Bayer announced today initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational targeted alpha ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

Long-term use of statins may delay or deflect the development of hepatocellular carcinoma in adults with chronic liver disease, as well as in the general population, emerging research, including ...

Hepatocellular carcinoma (HCC ... The risk factors for developing HCC are primarily related to underlying liver diseases, ...

Agenus Inc. (Nasdaq: AGEN), a clinical-stage immuno-oncology company, today announced updated data from the hepatocellular carcinoma (HCC) cohort of its ongoing Phase 1 study evaluating botensilimab ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, ...

And in patients with type 2 diabetes at risk for metabolic dysfunction-associated steatotic liver disease, a two-tier ...

EvoLiver, a blood test that detects early-stage liver cancer with high accuracy, has gained breakthrough device designation ...

Replimune Group, Inc.'s RP1 + OPDIVO for advanced melanoma gains FDA Priority Review. PDUFA date: July 22, 2025. Read more on ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...